Royalty Pharma (RPRX) Return on Capital Employed (2020 - 2026)

Royalty Pharma has disclosed Return on Capital Employed across 7 years of filings, most recently posting 8.28% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 8.28%, down 308.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.28% (down 308.0% YoY), and the FY2025 annual result was 8.53%, up 48.0% from the prior year.
• Return on Capital Employed came in at 8.28% for Q1 2026 at Royalty Pharma, roughly flat from 8.27% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 11.36% in Q1 2025 to a low of 1.91% in Q4 2022.
• The 5-year median for Return on Capital Employed is 7.66% (2024), against an average of 6.81%.
• Across the five-year window, Return on Capital Employed tumbled 629 bps in 2022 and jumped 744 bps in 2023, its largest moves.
• Royalty Pharma's Return on Capital Employed stood at 1.91% in 2022, then soared by 390 bps to 9.35% in 2023, then declined by 18 bps to 7.66% in 2024, then gained by 8 bps to 8.27% in 2025, then increased by 0 bps to 8.28% in 2026.
• The last three Return on Capital Employed figures came in at 8.28% (Q1 2026), 8.27% (Q4 2025), and 8.37% (Q3 2025), per Business Quant data.